Verona Pharma Plc ADR (NASDAQ: VRNA) is 81.09% higher on its value in year-to-date trading and has touched a low of $11.45 and a high of $81.73 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The VRNA stock was last observed hovering at around $81.20 in the last trading session, with the day’s gains setting it 2.9%.
Currently trading at $84.10, the stock is 16.35% and 26.75% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.11 million and changing 3.57% at the moment leaves the stock 71.95% off its SMA200. VRNA registered 609.70% gain for a year compared to 6-month gain of 111.09%. The firm has a 50-day simple moving average (SMA 50) of $65.9919 and a 200-day simple moving average (SMA200) of $48.623474.
The stock witnessed a 16.39% loss in the last 1 month and extending the period to 3 months gives it a 27.48%, and is 12.04% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.32% over the week and 3.14% over the month.
Verona Pharma Plc ADR (VRNA) has around 209 employees, a market worth around $7.16B and $118.55M in sales. Fwd P/E is 77.71. Profit margin for the company is -138.52%. Distance from 52-week low is 634.19% and 2.90% from its 52-week high. The company has generated returns on investments over the last 12 months (-34.98%).
The EPS is expected to grow by 153.85% this year.
Verona Pharma Plc ADR (VRNA) Top Institutional Holders
316.0 institutions hold shares in Verona Pharma Plc ADR (VRNA), with institutional investors hold 101.92% of the company’s shares. The shares outstanding are 85.13M, and float is at 76.70M with Short Float at 10.52%. Institutions hold 90.83% of the Float.
The top institutional shareholder in the company is RA CAPITAL MANAGEMENT, L.P. with over 7.63 million shares valued at $110.37 million. The investor’s holdings represent 1.1775% of the VRNA Shares outstanding. As of 2024-06-30, the second largest holder is MORGAN STANLEY with 0.86 million shares valued at $12.49 million to account for 1.0663 of the shares outstanding. The other top investors are NEA MANAGEMENT COMPANY, LLC which holds 5.58 million shares representing 0.8616% and valued at over $80.76 million, while DEEP TRACK CAPITAL, LP holds 0.6171 of the shares totaling 4.0 million with a market value of $57.84 million.
Verona Pharma Plc ADR (VRNA) Insider Activity
The most recent transaction is an insider sale by Hahn Mark W, the company’s Chief Financial Officer. SEC filings show that Hahn Mark W sold 204,864 shares of the company’s common stock on May 29 ’25 at a price of $9.33 per share for a total of $1.91 million. Following the sale, the insider now owns 12.68 million shares.
Verona Pharma Plc ADR disclosed in a document filed with the SEC on May 28 ’25 that Hahn Mark W (Chief Financial Officer) sold a total of 162,704 shares of the company’s common stock. The trade occurred on May 28 ’25 and was made at $9.30 per share for $1.51 million. Following the transaction, the insider now directly holds 12.88 million shares of the VRNA stock.
Still, SEC filings show that on May 27 ’25, Hahn Mark W (Chief Financial Officer) disposed off 32,432 shares at an average price of $9.53 for $0.31 million. The insider now directly holds 13,046,560 shares of Verona Pharma Plc ADR (VRNA).
